French CROs have eye on niche market

By staff reporter

- Last updated on GMT

Related tags Clinical trial Pre-clinical development

Two French contract research organisations (CROs) that specialise
in ophthalmology have banded together to offer specialised services
to this niche market.

The merger is being dubbed by the firms as unique, in that it "establishes the first global drug-development services provider to be totally dedicated to ophthalmology".​ However, the amalgamation is seemingly just a formalisation of an existing relationship between the two CROs - they were both established within five years of each other by the same person, Pierre-Paul Elena, who has also served as president for the two companies. Iris Pharma's focus is on preclinical research in the field, while Clirophtha runs Phase I-IV clinical trials throughout Western and Eastern Europe, North Africa, India, South Arabia and North America. Under their new united front, they will offer global customers "a complete range of [ophthalmology] services"​ under the name of Iris Pharma, including bioanalysis; non-GLP pre-formulation; pre-clinical studies and services; clinical trials and supporting functions; and consulting.

Related news

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us

Products

View more

Webinars